93 results
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
26 Mar 19
Entry into a Material Definitive Agreement
7:53am
, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other … of measuring ocular itching following environmental exposure to allergen Environmental (outdoor) exposure Chamber (controlled environment) exposure Expected
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
26 Sep 18
Regulation FD Disclosure
7:47am
, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things … corneal region, and 4 in sum corneal 2 staining score in sum conjunctival Demonstrate Controlled Adverse Environment (CAE) response OD = Ocular
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
31 Oct 19
Regulation FD Disclosure
7:38am
, industry environment and potential growth opportunities, among other things. The results of earlier clinical trials may not be predictive of future … environment and potential growth opportunities, among other things. The results of earlier clinical trials may not be predictive of future results. Forward
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
6 Jun 19
Submission of Matters to a Vote of Security Holders
6:31am
milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities … , regulatory review, and other factors. Methods Development Trials (Environment / Chamber) Results June 2019
DRY EYE DISEASE ALLERGIC CONJUNCTIVITIS
8-K
EX-99.1
ALDX
Aldeyra Therapeutics Inc
21 Dec 21
Regulation FD Disclosure
7:10am
, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth
8-K
EX-99.1
t3pui02ez yu
25 Jun 19
Regulation FD Disclosure
8:00am
8-K
EX-99.1
6unqv5891u0h nsc3zma
28 Mar 24
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
7:01am
8-K
EX-99.1
fazfhp7216jmio6
28 Nov 23
Regulation FD Disclosure
7:16am
8-K
EX-99.1
pa1toka9pi8mqlg
29 Nov 22
Other Events
8:05am
8-K
EX-99.1
xuq6e8z
20 May 20
Regulation FD Disclosure
7:43am
8-K
EX-99.1
kkj 5vzcy9fpl
8 Jun 22
Submission of Matters to a Vote of Security Holders
7:30am
8-K
EX-99.1
urv1s e5lw
14 Sep 22
Dry Eye Disease NDA for Reproxalap Expected to be Submitted in the Fourth Quarter of 2022
8:06am
8-K
EX-99.1
a4fe5ekw5x7w wb
27 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
iwaeh4dvxs1x
27 Apr 21
Regulation FD Disclosure
8:00am
8-K
EX-99.1
jhc1ffcrp o2
19 Dec 23
Regulation FD Disclosure
7:05am
8-K
EX-99.1
lfl 6t9m24lho5
6 Oct 22
Regulation FD Disclosure
7:05am
8-K
EX-99.1
ro2xy9cbf4 g9djv
10 Nov 22
Results of Operations and Financial Condition
7:06am
8-K
EX-99.1
jih3hf53m849796n2vt
7 Jan 21
Regulation FD Disclosure
7:51am
8-K
EX-99.1
8cz8og288pj ksm
29 Jun 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
y7gn0 vr2j
15 Jun 23
Regulation FD Disclosure
7:01am